Tags » Civil Justice & Litigation

'In re Lipitor': Fourth Circuit Smacks Down Result-Oriented Expert Testimony

Featured Expert Contributor, Judicial Gatekeeping of Expert Evidence

By Evan M. Tager, a Partner in the Washington, DC office of Mayer Brown LLP, with  2,148 more words

Civil Justice & Litigation

No Infinite Legal Duty: Arizona Supreme Court Rejects "Take Home" Asbestos Liability Theory

By Darrian Matthews, a 2018 Judge K.K. Legett Fellow at Washington Legal Foundation who will be entering her third year at Texas Tech University School of Law in the fall. 982 more words

Civil Justice & Litigation

Trio of Soda Cases Test the Limits of Attorney-Driven Class Action Lawsuits

Guest Commentary

By Jeffrey B. Margulies, Partner-in-Charge of the Los Angeles, CA office of Norton Rose Fulbright US LLP.

The approach of many plaintiff consumer class-action lawyers is not difficult to discern: Concoct a factual theory to support a claim under California’s consumer-friendly laws that survives a motion to dismiss and a motion for class certification. 1,507 more words

Civil Justice & Litigation

Neither Reason nor Science Supports Class Actions against Diet Soda Makers

A Food Court Follies Analysis

No doubt, many a diet soda will be consumed this weekend. Will any of those consumers, though, purchase that soda—in reliance on the manufacturers’ devious use of “diet”—because they think it will assist in weight loss? 689 more words

Civil Justice & Litigation

Update: Federal District Court Rejects Minority View on Pharma "Innovator Liability"

In a recent post, West Virginia’s High Court Rejects Novel Theory of “Innovator Liability”, WLF Senior Litigation Counsel Cory Andrews discussed a state court decision that declined liability on a pharmaceutical manufacturer for alleged harms caused by a drug it did not produce. 362 more words

Civil Justice & Litigation

West Virginia’s High Court Rejects Novel Theory of “Innovator Liability”

Should the law recognize a plaintiff’s tort claims against a branded drug manufacturer when the drug that allegedly caused the plaintiff’s injuries was manufactured and sold by the defendant’s generic competitor? 624 more words

Civil Justice & Litigation

Update: Ninth Circuit Softens its Decision in Flushable Wipes Case

Guest Commentary

By Lucía Roibal, an Associate with Morrison & Foerster LLP in the firm’s San Francisco, CA office. This commentary is reposted with permission, originally appearing on May 17, 2018 in the firm’s  888 more words

Civil Justice & Litigation